Systemic lupus erythematosus-associated irreversible organ/system damage was previously associated with various clinical and demographic features. We analysed the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI) in a cohort of 151 Israeli patients followed for a mean (§ s.d.) period of 45.7§ 37.4 months. Mean score of SLICC/ACR DI at the first and last encounters were 0.17§ 64 and 1.64§ 2.1, respectively (P < 0.0001). Multiple logistic regression analyses disclosed a statistically significant positive correlation with corticosteroid and cyclophosphamide therapy. Hydroxychloroquine therapy was significantly associated with lower SLICC/ACR DI. Although the size of our study group did not allow us to find specific organs/systems which were associated with the protective effect of hydroxychloroquine, we suggest this is due to the antiatherogenic effects attributed to antimalarial therapy in SLE.
Gladman D , Ginzler E , Goldsmith C et al. The development and validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus . Arthritis Rheum1996-1996; 39: 363–369 .
2.
Gladman DD , Urowitz MB , Goldsmith C et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus . Arthritis Rheum1997; 40: 809–813 .
3.
Gladman DD , Goldsmith CH , Urowitz MB et al for the Systemic Lupus International Collaborating Clinics. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International comparison . J Rheumatol2000; 27: 373–376 .
4.
Mok CC , Lee KW , Ho CTK , Lau CS , Wong RWS . A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population . Rheumatology2000; 39: 399–406 .
5.
Stoll T , Seifert B , Isenberg DA . SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus . Br J Rheumatol1996; 35: 248–254 .
6.
Lotstein DS , Ward MM , Bush TM , Lambert RE , van Vollenhoven R , Neuwelt CM . Socioeconomic status and health in women with systemic lupus erythematosus . J Rheumatol1998; 25: 1720–1729 .
7.
Sutcliê N , Clarkeí AE , Gordonî C , Farewelli V , Isenberg DA . The association of socioeconomic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus . Rheumatology1999; 38: 1130–1137 .
8.
Rivest C , Kew RA , Welsing PMJ et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus . J Rheumatol2000; 27: 680–684 .
9.
Nossent JC . SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis . J Rheumatol1998; 25: 654–659 .
10.
Gilboe IM , Kvein TK , Husby G . Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 y . J Rheumatol2001; 28: 266–274 .
11.
Wallace DJ . Antimalarial agents and lupus . Rheum Dis Clin N Am1994; 20: 243–263 .
12.
The Canadian Hydroxychloroquine Study Group . A randomized study on the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . New Engl J Med1991; 324: 150–154 .
13.
The Canadian HydroxychloroquineStudy Group . A long term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus . Lupus1998; 7: 80–85 .
14.
Wallace DJ , Metzger AL , Steicher VJ , Turnbull BA , Kern PA . Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med1990-1990; 89: 322–326 .
15.
Petri M . Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis . Lupus1996; 5: S16–S22 .
16.
Hodis HN , Quismorio FP Jr , Wickham E , Blankenhorn DH . The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus . J Rheumatol1993; 20: 661–665 .
17.
Rahman P , Gladman DD , Urowitz MB , Yuen K , Hallett D , Bruce IN . The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol1999-1999; 26: 325–330 .
18.
Tam LS , Gladman DD , Hallett DC , Rahman P , Urowitz MB . Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus . J Rheumatol2000; 27: 2142–2145 .
19.
Wallace DJ . Does hydroxychloroquinesulfate prevent clot formation in systemic lupus erythematosus?Arthritis Rheum1987; 30: 1435–1436 .
20.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271–1277 .
21.
Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH , and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients . Arthritis Rheum1992; 35: 630–640 .
22.
Rahman P , Gladman DD , Urowitz MB , Hallett D , Tam LS . Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus . Lupus2001; 10: 93–96 .
23.
Zonana-Nacach A , Camargo-Coronel A , Yáñez P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration . Lupus1998; 7: 119–123 .
24.
Stoll T , Sutcliffe N , Klaghofer R , Isenberg DA . Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage? A prospective study . Ann Rheum Dis2000; 59: 832–835 .
25.
Fortin PR , Abramowicz M , Neville C et al. Impact of disease activity and cumulative damage on the health of lupus patients . Lupus1998; 7: 101–107 .
26.
Gladman DD , Urowitz MB , Ong A , Gough J , MacKinnon A . Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life . Clin Exp Rheumatol1996; 14: 305–308 .
27.
Abu-Shakra M , Lorber M , Neumann L , Buskila D . Features of SLE in various ethnic groups in Israel . Clin Exp Rheumatol1997; 15: 181–184 .
28.
Petterson T , Pukkala I , Teppo L , Friman C . Increased risk of cancer in patients with systemic lupus erythematosus . Ann Rheum Dis1992; 31: 427–439 .
29.
Abu-Shakra M , Gladman DD , Urowitz MB . Malignancy in systemic lupus erythematosus . Arthritis Rheum1996; 39: 1050–1054 .
30.
Mellemkjoer L , Andersen V , Linet MS , Gridley G , Hoover R , Olsen JH . Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus . Arthritis Rheum1997; 40: 761–768 .
31.
Sultan SM , Ioannou Y , Isenberg DA . Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review . Rheumatology2000; 39: 1147–1152 .
32.
Urowitz MB , Bookman AAM , Koehler BE , Gordon DA , Smythe HA , Ogryzlo MA . The bimodal mortality of systemic lupus erythematosus . Am J Med1976; 60: 221–225 .
33.
Rhaman P , Gladman DD , Urowitz MB , Hallett D , Tam LS . Corticosteroid induced morbidity in SLE . Arthritis Rheum1999; 42: S96-S96 .
34.
Petri M , Perez-Gutthann S , Spence D , Hochberg MC . Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med1992; 93: 513–519 .
35.
Manzi S , Neilahn EN , Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study . Am J Epidemiol1997; 145: 408–415 .
36.
Bruce IN , Gladman DD , Urowitz MB . Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study . Clin Exp Rheumatol1998; 16: 435–440 .
Zonana-Zacach A , Barr SG , Magder LS , Petri M . Damage in systemic lupus erythematosus and its association with corticosteroids . Arthritis Rheum2000; 43: 1801–1808 .
39.
Pons F , Peris P , Guanabens N et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women . Br J Rheumatol1995; 34: 742–746 .
40.
Kipen Y , Buchbinder R , Forbes A , Strauss B , Littlejohn G , Morand E . Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids . J Rheumatol1997; 24: 1922–1929 .
41.
Petri M . Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update . Arthritis Care Res1995; 8: 137–145 .
42.
Houssiau FA , Lefebvre C , Depresseux G , Lambert M , Devogelaer JP , Nagant de Deuxchaisnes C . Trabecular and cortical bone loss in systemic lupus erythematosus . Br J Rheumatol1996; 35: 244–247 .
43.
Ramsey-Goldman R , Dunn JE , Huang C-F et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data . Arthritis Rheum1999; 42: 882–890 .
44.
Mok CC , Lay CS , Wong RW . Risk factors for vascular bone necrosis in systemic lupus erythematosus . Br J Rheumatol1998; 37: 895–900 .
45.
Mont MA , Glueck CJ , Pacheco IH , Wang P , Hungerford DS , Petri M . Risk factors for osteonecrosis in systemic lupus . J Rheumatol1997; 24: 654–662 .
46.
Migliaresi S , Picillo U , Ambrosone L et al. Avascular necrosis in patients with SLE; relation to corticosteroid therapy and anticardiolipin antibodies . Lupus1994; 3: 37–41 .
47.
Selzer F , Sutton-Tyrrell K , Fitzgerald S , Tracy R , Kuller L , Manzi S . Vascular stiffness with systemic lupus erythematosus . Hypertension2001; 37: 1075–1082 .
48.
Lakshminarayanan S , Walsh S , Mohanraj M , Rothfield N . Factors associated with low bone mineral density in female patients with systemic lupus erythematosus . J Rheumatol2001; 28: 102–108 .
